#oncologresearch #cancerbiology @Nature The #KRAS crowd targets its next cancer mutations. Clinic-ready inhibitors, degraders and molecular glues are pushing cancer frontiers by targeting KRAS variants including KRAS-G12D.
📌 https://www.nature.com/articles/d41573-023-00015-x.pdf
📌 https://www.nature.com/articles/d41573-019-00195-5.pdf
📌 https://www.cancer.gov/research/key-initiatives/ras

#oncologresearch @Nature #Clinicalperspectives #CARTCell #Immunobiology and mechanisms of resistance .Targets of #CARTCell therapies with clinical evidence of efficacy
📌 https://www.nature.com/articles/s41586-023-05707-3.pdf
📌 https://www.nature.com/nature/volumes/614/issues/7949

#oncologresearch #Cancerbiology #ScienceMagazine #precisionmedicine #precisionimmunotherapy & Understanding of the effects that both #immunotherapy & conventional Tx exert on the immune microenvironment will enable more precise & rational combinations of complementary Cancer Rx in patients who are nonresponsive to current Tx
https://www.science.org/doi/10.1126/science.adg5585?utm_campaign=SciMag&utm_source=Twitter&utm_medium=ownedSocial

#oncologresearch @kochinstitute A new study from the Spranger Lab pinpoints a reason why lung cancer doesn’t respond well to #immunotherapy: lymph nodes near the lungs create an environment that weakens #Tcell responses to tumors.
https://news.mit.edu/2023/lung-cancer-t-cells-doesnt-respond-well-immunotherapy-0202